OpenAlex
PricingAboutJobs
Log inGet started
Work

Which drug, and when, for patients with BRAF-mutant melanoma?

HTML

Year: 2013
Type: review
Source: The Lancet Oncology
DOI: 10.1016/s1470-2045(12)70539-9
Authors: Sekwon Jang, Michael B Atkins
Institutions: MedStar Washington Hospital Center, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: BRAF V600 mutation, metastatic melanoma, BRAF inhibitors, vemurafenib, dabrafenib, trametinib, ipilimumab, interleukin-2, MAPK signaling, cutaneous squamous cell carcinoma, drug resistance, treatment sequencing, immunotherapy
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2116362236
FWCI: 3.691
Cites: 70
Cited by: 203
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security